No Laughing Matter: Avanir Resubmits Neurodex NDA

The firm is requesting priority review for involuntary emotional expression disorder.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet